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In Europe,  azacitidine  is  the  only  hypomethylating  agent  approved  for the  treatment  of patients  with
int-2-/high-risk  myelodysplastic  syndromes,  offering  signiﬁcantly  improved  survival  compared  with
conventional  care. However,  not  all patients  treated  with  azacitidine  respond  to treatment,  and  the  vast
majority  of  responders  subsequently  relapse.  Currently,  no  standard  care  regimens  have  been  established
for patients  after failure  of azacitidine.  Here,  we  discuss  treatment  options  after  loss  of  response  or  pro-
gression  on  azacitidine.  In  addition,  we  brieﬂy  consider  optimization  of  ﬁrst-line  treatment  along  withDS
ypomethylating agents
zacitidine
onsensus
elapse
efractory
potential  biomarkers  for identifying  and  monitoring  response  during  treatment  with  azacitidine.
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. Introduction
Myelodysplastic syndromes (MDS) are clonal hematopoietic
isorders characterized by ineffective hematopoiesis, cytologi-
al dysplasia, cytopenias and an increased risk of progression to
cute myeloid leukemia (AML) [1]. MDS  usually affect the elderly
nd are often associated with diminished quality of life (QoL)
nd poor prognosis, especially in higher-risk cases [2]. Progno-
is among patients with MDS  is estimated using the International
rognostic Scoring System (IPSS) [3], which was recently revised
IPSS-R), and now considers bone marrow (BM) blast percentage,
he number and severity of cytopenias and additional cytogenetic
isk categories [4,5]. Without disease-modifying therapy patients
ith IPSS high-risk MDS  generally have a life expectancy of <6
onths following diagnosis [3]. Until some years ago, active treat-
ent options for patients with high-risk MDS  were limited to
ematopoietic stem cell transplantation (HSCT) and chemother-
py. While HSCT remains the only potentially curative treatment
n eligible candidates, it is rarely applicable to the majority (mainly
ue to advanced age and/or comorbidities) [6], and chemother-
py has shown limited efﬁcacy [7,8] and should be reserved
or patients with a normal karyotype. However, alternative non-
ggressive treatment options that can improve outcomes in a
roader range of patients are now available or are under devel-
pment.
In recent years, new therapeutic strategies have been devel-
ped with the hypomethylating agents (HMAs), decitabine and
zacitidine. These nucleoside analogs are both approved by the US
ood and Drug Administration (FDA) for the treatment of MDS. In
he conﬁrmatory AZA-001 trial, azacitidine was shown to signiﬁ-
antly prolong overall survival (OS) compared with conventional
are regimens (CCR; 24.5 months vs. 15.0 months, respectively;
 = 0.0001) in patients with intermediate (int)-2-/high-risk MDS  or
ML  with 20–30% BM blasts (World Health Organization-deﬁned
ML  [WHO-AML]) who achieved any kind of response, includ-
ng hematologic improvement (HI) [2,9]. These results led to its
pproval by the European Medicines Agency in these patient
ubsets and in patients with chronic myelomonocytic leukemia
CMML) with >10% BM blasts [10]. As decitabine was not able to
emonstrate signiﬁcant survival beneﬁts in MDS  patients in Phase
 trials, and for that reason has not received European authoriza-
ion for use in MDS, azacitidine is the only approved therapy for
PSS int-2-/high-risk MDS  in Europe.
Despite the efﬁcacy and reported activity of HMAs in large
umbers of patients, these agents are not curative; principal clin-
cal studies and emerging patient registry data indicate that as
any as 40% of patients do not respond to treatment or subse-
uently relapse (Table 1). In the AZA-001 trial which assessed
atients with IPSS higher-risk MDS, 29% of patients treated with
zacitidine (75 mg/m2/day for 7 continuous days during every 28-
ay cycle) failed to achieve a response (complete response [CR],
artial response [PR] or stable disease [SD]) and most patients
ho responded experienced disease progression within 2 years . . . .  . . . . . .  . . . . . . .  .  . .  . . .  . .  . . . . . . . . . . .  . . .  . . . .  . . . .  .  . . . . .  .  . .  . .  .  . . . . . . . . .  .  .  . 1389
[2]. Similarly, in the CALGB-8421 and -9221 studies which also
assessed azacitidine (at the same dose and schedule as in AZA-
001), 40–56% of patients failed to achieve a response (CR or PR
or HI) [11,12]. Recently published data from the Groupe Fran-
cophone des Myélodysplasies (GFM) MDS  patient registry have
indicated that 40% of patients treated with azacitidine in a ‘real-
world’ setting failed to respond (22% of patients achieved SD
without HI; 18% progressed) [13]. Mechanisms of resistance to
azacitidine have not been fully elucidated but may be due to intrin-
sic biological characteristics of the disease such as presence of
speciﬁc gene mutations, e.g. TP53, upregulation of BCL2 family pro-
teins, e.g. BCL2L10 [14], DNA methylation density, and differential
expression of the enzyme UCK1 involved in nucleoside metabolism
[15].
Once patients lose their response or progress on azacitidine,
their prognosis is poor [17,18]. In a recent analysis of 435 patients
with high-risk MDS  and primary (no response) or secondary (loss of
response) failure to azacitidine, median OS after azacitidine failure
was 5.6 months and 2-year survival probability was 15% [18]. Sim-
ilarly, in an analysis of 59 patients who  had relapsed on or were
refractory to azacitidine, median OS was  252 days and the esti-
mated 12-month survival rate was  only 20% [19]. At present, the
absence of a standard salvage treatment following azacitidine fail-
ure [18] constitutes a major unmet medical need in patients with
higher-risk MDS.
Given the poor outcomes in patients following failure of azac-
itidine, considerable efforts have been made to ensure optimal
response rates with ﬁrst-line therapy. Recommendations have
been published elsewhere, and have highlighted, for example, the
need to treat patients for at least 6 cycles or until disease progres-
sion with the approved dose and schedule (75 mg/m2/day for 7
continuous days during every 28-day cycle) [20,21]. There has also
been much research into the possibility of improving response rates
or the depth and durability of response with azacitidine, by com-
bining it with other epigenetic modifying agents such as histone
deacetylase (HDAC) inhibitors, lenalidomide, All trans retinoic acid
and other agents [22–29]. However, despite some early promis-
ing data, no combination regimens to-date have been validated
in randomized clinical trials, some of which are still ongoing. At
the moment, therefore, it is imperative that viable post-azacitidine
salvage options are developed.
In order to gain an up-to-date perspective on the man-
agement of patients relapsed or refractory to azacitidine, a
panel of international experts was convened to discuss; (1)
the best current treatment approaches for patients failing
azacitidine and (2) the most promising investigational agents
currently under development in these patients. Given the poor
prognosis of relapsed/refractory patients, the panel also dis-
cussed; (3) how best to monitor treatment to facilitate earlyﬁrst-line treatment with azacitidine; and (4) recent develop-
ments in biomarkers that may be able to predict and monitor
response.
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Table  1
Principal clinical studies of azacitidine and real-world data in patients with IPSS higher-risk MDS  (azacitidine-treated patients only).
Study Baseline
characteristics
Treatment Response Progression/relapse Survival
Fenaux et al. (2009)
AZA-001 [2]
• Patients, n = 179 • Azacitidine 75 mg/m2/day
for 7 days every 28 days (SC)
• CR: 17%
• PR: 12%
• SD: 42%
• HI: 20%
• Time to AML  progression:
17.8 months
• Time to disease
progression, relapse after
CR or PR, and death:
14.1 months
• Duration of CR, PR or HI:
13.6 months
• Duration of CR + PR:
3.0 months
• OS: 24.5 months
Silverman et al.
(2002)
CALGB-9221 [11]
• Patients, n = 99 • Azacitidine 75 mg/m2/day
for 7 days every 28 days (SC)
• CR: 7%
• PR: 16%
• HI: 37%
• No response: 40%
• Time to AML  progression
or death: 21 months
• Time to treatment
failure: 9.1 months
• OS: 20 months
Silverman et al.
(2006)
CALGB-8921 [16]
• Patients, n = 70 • Azacitidine 75 mg/m2/day
for 7 days every 28 days (SC)
• CR: 17%
• PR: 0%
• HI: 23%
• No response: 60%
• NR • NR
Silverman et al.
(2006)
CALGB-8421 [16]
• Patients, n = 48 • Azacitidine 75 mg/m2/day
for 7 days every 28 days (IV)
• CR: 15%
• PR: 2%
• HI: 27%
• No response: 56%
• NR • NR
Patient  registries
Itzykson et al.
(2011)
GFM registry [13]
• Patients, n = 282 • Azacitidine 75 mg/m2/day
for 7 days every 28 days:
72%
• Azacitidine <75 mg/day
for 7 days every 28 days: 6%
• Azacitidine 75 mg/day for
5  days every 28 days: 19%
•  Azacitidine <75 mg/day
for 5 days every 28 days: 3%
• CR: 14%
• PR: 3%
• mCR: 11%
• SD with HI: 15%
• SD without HI:
22%
PD: 18%
• Duration of CR:
10.4 months
• Duration of PR:
9.8 months
• Duration of mCR:
8.0 months
• Duration of SD with HI:
7.9 months
• Median duration of any
response: 9.5 months
• OS: 13.5 months
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dR, complete response; HI, hematologic improvement; IV, intravenous; mCR, marr
esponse; SC, subcutaneous; SD, stable disease; TTP, time to progression.
. Panel recommendations for the treatment of patients
ith higher-risk MDS  following azacitidine failure
.1. What is the best current treatment approach in patients after
zacitidine?
.1.1. Background
Currently, there are few data regarding the treatment and out-
omes of patients post-azacitidine with only one large analysis
ublished to-date [18]. In this study, clinical outcomes were com-
ared in 270 patients with higher-risk MDS  who  received HSCT
n = 37), intensive chemotherapy (n = 35), low-dose chemotherapy
n = 32), investigational agents (n = 44) or BSC (n = 122) follow-
ng azacitidine failure. HSCT was associated with the best clinical
utcomes with an overall response rate (ORR) of 68%. Median
S in these patients was 19.5 months, which was signiﬁcantly
reater than that observed with either best supportive care (BSC:
.1 months; p < 0.001) or intensive chemotherapy (8.9 months;
 = 0.008). Among patients who received investigational therapies
including amongst others, kinase inhibitors, epigenetic agents,
enalidomide or thalidomide) median OS was 13.2 months, which
as not signiﬁcantly different from HSCT results, but was  signiﬁ-
antly longer compared with all other treatment options. Response
ate in patients who received intensive chemotherapy was poor
t 14%, with a median OS of 8.9 months. Patients who received
ow-dose chemotherapy had a median OS of 7.3 months with no
bjective responses. Based on these data, only HSCT seems to offer
he best potential for longer term disease control following azaciti-
ine failure. Overall however, treatment outcomes post-azacitidine; NR, not reported; ORR, overall response rate; PD, progressive disease; PR, partial
remain disappointing. Although investigational therapies appear to
extend survival, these results should be interpreted with caution,
given the inherent selection bias introduced by entry criteria for
clinical trials.
In the ﬁrst-line setting, intensive chemotherapy is generally
considered of limited utility in higher-risk MDS  patients due to
poor tolerability, limited efﬁcacy and high risk of relapse. How-
ever, some smaller studies have assessed chemotherapy in the
post-azacitidine setting. In one study, CLAG-M (cladribine, cytara-
bine, G-CSF, mitoxantrone; n = 25) and standard 3 + 7 (anthracycline
and cytarabine, n = 24) regimens were assessed in non-randomized
patients with secondary AML, arising from MDS, after failure of
HMAs (azacitidine or decitabine) [30]. Median OS was signiﬁcantly
better in patients treated with CLAG-M compared with those who
received 3 + 7 chemotherapy (202 days vs. 86 days, p = 0.025). More-
over, more patients in the CLAG-M cohort were able to proceed to
allogeneic HSCT (28% vs. 4%; p = 0.024). In another retrospective
study, Bello, et al. assessed intensive chemotherapy in 61 patients
with secondary AML  post-MDS of whom 45% had previously been
treated with HMAs (azacitidine or decitabine) or lenalidomide.
Among these patients, 32% achieved a CR or marrow CR (mCR) with
low platelets, and median OS was  only 3.7 months [31]. Thus, the
role of intensive chemotherapy in the salvage setting appears to
remain uncertain and requires further investigation.2.1.2. Views and recommendations of the panel
The panel agreed that HSCT seems to offer encouraging out-
comes following azacitidine therapy, with seemingly reduced
impact caused by the presence of active disease at the time of
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ransplant. Furthermore, it was suggested that eligibility for trans-
lantation should be assessed as early as possible before and during
reatment with azacitidine. Accumulating evidence indicate that
zacitidine can facilitate HSCT in some patients who  were previ-
usly ineligible [32,33]. However, it was noted that only limited
umbers of patients who received azacitidine are likely to be eli-
ible for transplantation, or become ﬁt to receive pre-transplant
onditioning therapy in this setting.
There were conﬂicting views within the panel regarding
he role of intensive chemotherapy following azacitidine fail-
re. Some panel members reported that, in their experience,
arrow regeneration is poor in patients who undergo inten-
ive chemotherapy post-azacitidine. Furthermore, it was noted
hat relapsed/refractory MDS  patients with a complex karyotype
re unlikely to respond, as is the case in the front-line setting
34]. Therefore, some panel members recommended that inten-
ive chemotherapy is only undertaken with a view to preparing
atients for subsequent HSCT. However, sporadic good responses
ere reported by other members of the panel. The panel concluded
hat more data needs to be collected in patients who have received
ntensive chemotherapy as a salvage treatment. Indeed, at present,
here is a lack of prospective clinical data and only limited case
eries reports.
.2. What are the key investigational strategies in the
ost-azacitidine setting?
.2.1. Background
Several promising investigational strategies are currently being
nvestigated in the post-azacitidine setting. Results from early clin-
cal trials are outlined in Table 2, and discussed brieﬂy here.
.2.1.1. Nucleoside analogs. Certain novel nucleoside analogs have
hown anti-leukemic activity in MDS  and AML  in the post-
zacitidine setting. For example, clofarabine in both oral and
ntravenous formulations has been assessed in patients with
igher-risk relapsed/refractory MDS. At doses of 15 and 30 mg/m2
V for 5 days, patients previously treated with HMAs (n = 22 and
 = 13, respectively) achieved response rates of 15–19% [35]. Addi-
ionally, in a study of 20 patients with HMA-refractory/relapsed
DS, oral clofarabine led to a 33% response rate and appeared to
e better tolerated than the IV formulation [38]. However, tolerabil-
ty concerns with this agent, such as prolonged myelosuppression,
nd hepatic and renal toxicities remain an important barrier when
onsidering clofarabine in this setting [35–37].
Sapacitabine, an oral deoxycytidine nucleoside analog, has also
emonstrated promising activity in patients with MDS  who  had
een previously treated with HMAs. Interim results from a Phase
 trial in patients who were refractory to azacitidine or decitabine
ndicated a post-treatment ORR of 14–19%, median OS of approx-
mately 8 months and acceptable tolerability when treated with
ral sapacitabine (200 mg  bid/300 mg  qd for 7 days every 4 weeks
r 100 mg  qd for 5 days a week × 2 weeks) [39]. Based on these
ata, further prospective trials of sapacitabine in this setting are
ngoing.
.2.1.2. HMAs. The HMAs azacitidine and decitabine have been
ssessed in several clinical trials for MDS  and AML. In the ﬁrst-line
etting, azacitidine is the only treatment to have demonstrated a
urvival advantage in patients with higher-risk MDS  ineligible for
ransplantation. However, no prospective, randomized trials of the
wo agents have been conducted. Currently, the only available com-
arisons are retrospective, observational analyses [51,52], which
hould be interpreted with caution given the inherent selection
ias of such studies. Importantly however, although azacitidine
nd decitabine are both DNMT inhibitors, they have differentrch 38 (2014) 1381–1391
mechanisms of action which could facilitate sequential treatment.
A key difference is that azacitidine is predominantly incorporated
into RNA (65–90%) with the remainder becoming incorporated
into DNA [53,54]. Decitabine, on the other hand is only incorpo-
rated into DNA [53]. Therefore, it is an oversimpliﬁcation to refer
to azacitidine as a DNA HMA  because this description overlooks
additional mechanisms of activity which affect RNA and protein
metabolism. Indeed, azacitidine and decitabine appear to have dif-
ferent effects on cell viability, protein synthesis, the cell cycle and
gene and protein expression [53,55]. Based on these differences, it
was hypothesized that patients may  not be cross-resistant to both
agents [17]. Some very limited data from 2 small studies suggest
that decitabine may  have activity in some patients who have failed
treatment with azacitidine. Response rates of 28% and 33%, respec-
tively, were achieved in these studies of 14 patients each, while OS
remained limited ranging from 6 to 12 months [40,42]. In addition,
in a recently reported retrospective analysis, sequential therapy
with decitabine after azacitidine elicited a median OS of 48 months
in 10 patients with predominantly lower-risk disease [41]. Based
on these results, further investigation of decitabine in this setting
is warranted.
Recently, a second-generation HMA  (SGI-110, a dinucleotide of
decitabine and deoxyguanosine), has been developed that poten-
tially offers improved clinical activity over decitabine based on
its improved resistance to degradation by cytidine deaminase and
favorable pharmacokinetic proﬁle. In an ongoing Phase 1/2 trial of
78 patients with relapsed or refractory AML/MDS, SGI-110 yielded
some responses in this heavily pre-treated population (AML: 6%;
MDS: 14%) and was well tolerated at doses higher than the biolog-
ically effective dose [56]. Further clinical studies of SGI-110 in the
relapsed/refractory setting are therefore warranted.
2.2.1.3. Tyrosine kinase inhibitors. A small number of tyrosine
kinase inhibitors (TKIs) are currently under investigation as post-
azacitidine salvage therapy. Notably, in a recent Phase 1/2 trial of
rigosertib, a dual PLK1/PI3K inhibitor, 50% of evaluable patients
demonstrated either a BM or peripheral blood response following
HMA  failure. Median OS was approximately 10 months [44]. As a
result, a Phase 3 trial comparing intravenous rigosertib with BSC
in patients with higher-risk MDS  refractory, relapsed or intoler-
ant to HMAs and with excess blasts has recently been undertaken
(NCT01241500) [57]. Although the primary endpoint of this trial
(median OS for the whole cohort) was not met, early subanaly-
ses indicate that a survival beneﬁt can be seen in patients who
had progressed or failed on prior HMAs who had been treated
with rigosertib + BSC compared with patients who  received BSC
alone (8.5 months vs. 4.7 months, p = 0.02) [58]. However, the same
improvement in OS was not seen in patients who had relapsed after
initially responding to treatment with HMAs [58]. In addition to this
study, a recent Phase 1 study of oral rigosertib in 37 patients with
low- and high-risk MDS  indicated that the drug was  bioavailable,
well tolerated and clinically active in patients who had received
prior therapy, including HMAs [45]. Further investigation of this
oral formulation is warranted.
Other agents include the epidermal growth factor receptor
(EGFR) TKI erlotinib, which has demonstrated some efﬁcacy follow-
ing ﬁrst-line treatment with either azacitidine or decitabine [46].
As preclinical data have indicated that the spectrum of activity of
erlotinib extends to JAK2 and other kinases [59], it may synergize
with HMAs. As such, it could be considered as a possible add-on
therapy in patients who are losing response to azacitidine.
Tosedostat is an orally available aminopeptidase inhibitor that,
similarly to TKIs, is thought to selectively block proliferation in
tumor cells. Having shown some activity in a Phase 1/2 trial in AML
[60], a Phase 3 randomized study is now planned in patients with
higher-risk MDS  and AML.
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Table 2
Trials of investigational agents in the post-azacitidine setting.
Agent Treatment schedule Prior treatment Patients Key ﬁndings Reference
Nucleoside analogs
Clofarabine 15–30 mg/m2 for 5 days every 4–8
weeks (IV)
Azacitidine or
decitabine
35 patients with high-risk MDS
or sAML (interim analysis)
• 6/35 patients (17%) achieved a
response
• Signiﬁcant myelosupression and
toxicity
Faderl et al. (2012)
[35]
Clofarabine 5–10 mg/m2 for 5 days every 4–8
weeks (IV)
Azacitidine ± decitabine
or lenalidomide
9 evaluable patients with MDS  • CR/PR: 22%
• HI: 22%
• Severe and prolonged pancytopenia
• Median duration of any response:
12 months
Lim et al. (2010)
[36]
Clofarabine 5–10 mg/m2 for 5 days every 4–8
weeks (IV)
Azacitidine 19 patients with higher-risk
MDS  or AML
• CR/PR: 11%
• mCR: 16%
• HI-any: 5
• 7 patients hospitalised due to fever or
bleeding
Braun et al. (2011)
[37]
Clofarabine 20–40 mg/m2 for 5 days every 4–8
weeks (oral)
Azacitidine or
decitabine
20 evaluable patients with
higher-risk MDS, AML  or CMML
• CR: 10%
• HI: 10%
• Myelosuppression was  common
Faderl et al. (2010)
[38]
Sapacitabine 100 mg/day every 5 days for 2 weeks or
300–400 mg/day every
7  days for 2 weeks
Azacitidine or
decitabine
61 patients with int-2 or
high-risk MDS  (interim
analysis)
• CR/CRp: 7%
• HI: 7%
• SD: 10%
• Well tolerated
Garcia-Manero
et al. (2012) [39]
Hypomethylating agents
Decitabine 20 mg/m2 for 5 days every 28-day cycle Azacitidine 14 patients with MDS  (interim
analysis)
• CR: 21%
• HI-P: 7%
• SD: 36%
• Non-hematologic grade 3–4 AEs: 29%
•  Febrile neutropenia: 33%
Borthakur et al.
(2008) [40]
Decitabine NR Azacitidine 21 evaluable patients with
MDS
• mCR: 10%
• Median OS from diagnosis:
48 months
Komrokji et al.
(2013) [41]
Decitabine NR Azacitidine 10 evaluable patients with
high-risk MDS  or AML
• 0/10 patients achieved a response
•  Median OS: 11.8 months
Prebet et al. (2011)
[18]
Decitabine ± gemtuzumab
ozogamicin (GO)
Decitabine: 20 mg/m2 for 5 days every
28-day cycle
GO: 3 mg/m2 on days 5 and 9 of every
28-day cycle
Azacitidine 9 patients with MDS, CMML  or
AML
• CR + PR + HI: 33%
•  Median OS in refractory patients:
2  months
•  Median OS in relapsed patients:
4 months
•  Two patients hospitalised due to
sepsis
Sanna et al. (2011)
[42]
SGI-110 Phase I dose escalation study (SC
administration)
Azacitidine or
decitabine
15 evaluable patients with
MDS
• mCR: 13%
• HI-any: 27%
• Generally well tolerated
Kantarjian et al.
(2012) [43]
1386
 
V
.
 Santini
 et
 al.
 /
 Leukem
ia
 R
esearch
 38
 (2014)
 1381–1391
Table 2 (Continued)
Agent Treatment schedule Prior treatment Patients Key ﬁndings Reference
Tyrosine kinase inhibitors
Rigosertib 1375 mg/m2/day IV infusion for 72 h
every 2 weeks
Azacitidine or
decitabine
18 evaluable patients with
MDS, AML  or CMML
• mCR: 22%
• HI: 11%
•  SD: 17%
•  Median OS in responders:
10.1 months
•  Median OS in
non-responders: 2 months
Navada et al.
(2012) [44]
BSC ± rigosertib Rigosertib: 1800 mg/m2/day IV
infusion for 72 h every 2 weeks
(1st 8 cycles), every 4 weeks thereafter
BSC: schedule not speciﬁed
Azacitidine or
decitabine
299 patients with higher-risk
MDS  (5–30% BM blasts)
• Primary endpoint not met
• Median OS for rigosertib + BSC
vs. BSC alone: 8.2 months vs.
5.8 months (p = 0.27)
•  Median OS for
rigosertib + BSC vs. BSC alone in
primary non-responders to
HMAs: 8.5 months vs. 4.7
months (p = 0.02)
•  Generally well tolerated
NCT01241500 [48]
Onoconova press
release, February
2014 [49]
Rigosertib Phase I dose escalation study (PO
administration)
Azacitidine,
decitabine,
lenalidomide or
ESA
37 patients with MDS • mCR: 5%
• TTP in IPSS higher-risk
patients: 16 weeks
Komrokji et al.
(2013) [45]
Erlotinib 150 mg/day for 16 weeks Azacitidine or
decitabine
35 evaluable patients with
MDS
• mCR: 9%
• HI: 6%
•  SD: 31%
•  Median OS: 6.8 months
• Manageable toxicity
Komrokji et al.
(2011) [46]
HDAC inhibitors
Vorinostat + LDAC Vorinostat: 400 mg/day for 7, 10 or 14
days
LDAC: 10–20 mg/m2/day for 14 days
Azacitidine or
decitabine
35 evaluable patients with
int-2 or high-risk MDS
• CRi/mCR: 11%
• HI: 1%
•  Median duration of response:
3 months (range 2–6)
• Median OS: 9.2 months
Prebet et al. (2012)
[47]
Panobinostat 30 mg three times weekly Azacitidine or
decitabine
10 patients with MDS (interim
analysis)
• SD: 70%
•  Three patients experienced
SAEs
• Well tolerated
Flinn et al. (2010)
[48]
Immunomodulatory agents
Lenalidomide 5–10 mg/day for 21 days every 28-day
cycle
Azacitidine 10 patients with MDS or AML  • CR: 30%
•  HI-E: 10%
•  Median duration of response:
6 months
•  Median OS post-AZA: 19.5
months
Prebet et al. (2012)
[49]
Lenalidomide + azacitidine 10 mg/day for 21 days every 28-day
cycle
Azacitidine 3 patients with higher-risk
MDS
• All 3 patients achieved a CR
•  Duration of CR: 5–7+ months
• Well tolerated
Sekeres et al.
(2011) [50]
AEs, adverse events; AML, acute myeloid leukemia; CMML,  chronic myelomonocytic leukemia; CR, complete response; HI, hematologic improvement; HI-E, hematologic improvement-erythroid; HI-P, hematologic improvement-
platelet;  IV, intravenous; LDAC, low dose cytarabine; mCR, marrow complete response MDS, myelodysplastic syndromes; NR, not reported; OS, overall survival; PR, partial response; SAE, serious adverse event; sAML, secondary
AML;  SD, stable disease; TTP, time to progression.
 Resea
2
m
i
2
l
t
t
b
2
t
t
t
y
a
p
o
d
w
e
l
2
e
n
F
p
t
t
a
t
m
n
s
t
o
t
e
l
D
p
p
a
a
p
1
3
t
g
t
a
a
S
p
t
t
l
p
tV. Santini et al. / Leukemia
.2.1.4. HDAC inhibitors. As well as ﬁrst-line combination regimens
entioned previously, some recent studies have assessed the activ-
ty of HDAC inhibitors in the salvage setting. For example, a Phase
 trial has indicated a possible role for vorinostat combined with
ow-dose chemotherapy in MDS  patients who have failed on azaci-
idine [47]. Panobinostat may  also be a useful combination agent in
he salvage setting, but is yet to demonstrate a signiﬁcant clinical
eneﬁt in ﬁrst-line treatment [48].
.2.1.5. Immunomodulatory agents. It was recently hypothesized
hat lenalidomide may  have activity in the post-azacitidine set-
ing given the two agents’ different mechanisms of action. Although
he precise molecular rationale for lenalidomide in this setting is
et to be elucidated, there is empirical evidence that it has clinical
ctivity post-azacitidine [49,50]. In a retrospective analysis of 10
atients (low-risk and high-risk MDS) who received at least 1 cycle
f lenalidomide (5 or 10 mg/day [both n = 5] for 21 days every 28
ays) post-azacitidine, an ORR of 40% and median OS of 19.5 months
as reported [49]. One may  speculate that the antiproliferative
ffects of azacitidine may  be complemented by the immunomodu-
atory effects of lenalidomide on the BM microenvironment [27,50].
.2.2. Views and recommendations of the panel
Overall, the panel agreed that despite intensive and ongoing
valuation of investigational agents in the post-azacitidine setting,
o convincing data currently exist to inform treatment decisions.
urthermore, in the absence of prospective comparative trials,
anel members stated that it is currently difﬁcult to compare
he relative merits of investigative salvage treatments. Therefore,
here is a clear and urgent need for additional clinical trials that
ssess novel salvage therapies as well as potential add-on strategies
o ﬁrst-line azacitidine. Consequently, all panel members recom-
ended that patients who have failed azacitidine therapy (and are
ot eligible for HSCT) should be enrolled in a clinical trial. Indeed, as
hown previously, treatment with experimental agents may  offer
he prospect for better survival than conventional chemotherapy
r BSC [18].
Panel members are personally engaged in a number of clinical
rials of investigational agents and regimens including rigosertib,
rlotinib and clofarabine. Some panel members have also used
enalidomide in patients who have failed on azacitidine therapy.
iscussing lenalidomide in a salvage setting, the panel agreed that
rospective studies in post-azacitidine patients were warranted,
articularly in patients who have a chromosome 5q deletion, either
s an isolated aberration or as part of a complex karyotype, but that
t present it cannot be recommended for routine use. Finally, the
anel agreed that HDAC inhibitors, decitabine and potentially SGI-
10 warrant further investigation in the post-azacitidine setting.
. Panel recommendations for monitoring patients during
reatment with azacitidine
Despite ongoing clinical investigations, no clear salvage strate-
ies in patients with relapsed/refractory MDS who have failed
reatment with azacitidine are currently available. Consequently,
ppropriate selection of patients for azacitidine in ﬁrst-line ther-
py is of paramount importance. To this end, the French Prognostic
core (FPS) has been developed, based on performance status,
resence or absence of circulating blasts and red blood cell (RBC)
ransfusion requirement, that categorizes prognosis in patients
reated with azacitidine [13]. As well as ensuring that patients most
ikely to beneﬁt from azacitidine receive it, it is important that
atients are monitored for early signs of relapse, particularly in
hose patients who are candidates for stem cell transplant, givenrch 38 (2014) 1381–1391 1387
the limited salvage options. Discussing appropriate monitoring of
patients, the panel considered the following questions.
3.1. When monitoring patients on azacitidine, how do you
distinguish between peripheral blood (PB) ﬂuctuations (during
response) and a true loss of response, and when should the BM be
assessed?
3.1.1. Background
Exacerbation of cytopenias and myelosuppression-related com-
plications are not unexpected in patients treated with azacitidine
and may  lead initially to deterioration of the clinical condition of
patients, especially during early treatment cycles. In the AZA-001
trial, anemia, neutropenia and thrombocytopenia were observed in
51.4%, 65.7% and 69.7% of patients treated with azacitidine, respec-
tively [21]. Proportionately more patients experienced hematologic
adverse events (AEs) during the ﬁrst 2 cycles of azacitidine com-
pared with later cycles [21]. Therefore, reductions in PB counts
should not necessarily be considered as evidence of primary or
secondary treatment failure, particularly when noted during early
treatment cycles.
3.1.2. Views and recommendations of the panel
In terms of monitoring patients for response, the panel agreed
that the most important parameter for assessing patients during
the ﬁrst 6 cycles was  regular assessment of PB counts rather than
BM assessment, given the correlation of PB counts with patients’
prognosis, QoL and overall wellbeing. BM assessment should be
undertaken, only after prior analysis of the PB, and after at least
6 cycles of azacitidine. In addition, the panel recommended that
BM analysis be performed in patients who appear to be primary
non-responders in the PB in order to conﬁrm that there is no exist-
ing or imminent response, and in secondary non-responders (i.e.
patients who had relapsed on azacitidine), to determine the cause
of cytopenia, e.g. infection, loss of cellularity, drug-related toxicity.
Regarding ﬂuctuations in PB counts, rapid changes, especially
in early cycles, may  be due to transient toxic effects of the drug
rather than disease progression. It is important therefore that drug-
related cytopenias are managed during treatment, without dose
reductions/delays if at all possible so as to maximize the chances
of response to azacitidine [21]. In contrast, loss of hematologic
response to azacitidine tends to be gradual and occur during later
cycles after a response has been achieved. As such, reappearance of
RBC-transfusion dependence (RBC-TD) in a patient who  had previ-
ously achieved RBC-transfusion independence (RBC-TI) is a likely
sign of impending relapse. To identify loss of response, all lineages
should be assessed over time to gauge an overall impression of
trends. Consequently, the panel agreed that the most important
indicators of loss of response to azacitidine and/or progression to
AML  were deteriorating cytopenias (which may  take several suc-
cessive measurements to conﬁrm) [61], an increase or recurrence
in transfusion requirements or emergence of circulating blasts.
Continuing their discussion the panel suggested that the follow-
ing observations could indicate relapse: a progressive decline in PB
counts over time that do not return to baseline levels; unexpected
changes in established, stable blood counts (after a hematologic
response is achieved); and a gradual decrease in platelet count with
or without an accompanying increase in PB blast count. Platelet lev-
els were considered a particularly sensitive parameter to monitor,
given their shorter circulation time compared with RBCs. Conse-
quently, reduced platelet counts are likely to be one of the earliest
indicators of pending disease relapse.Finally, when assessing response and improvement of response
in patients treated with azacitidine in clinical trials, some panel
members highlighted that it is important to remember that most
of the principal Phases 2 and 3 trials were conducted using
1388 V. Santini et al. / Leukemia Resea
Table  3
Emerging predictive factors of response to azacitidine.
Clinical factors
Positive Negative
Doubling of platelet count after ﬁrst
cycle [70]
Grade 3 BM ﬁbrosis [72]
Reduction in leukemic stem cells
during treatment [71]
ECOG PS > 2 [13]
Circulating blasts [13]
BM blasts >15% [13]
Transfusion dependence [13]
Previous therapy [13]
Molecular/cytogenetic factors
Positive Negative
Mutations in TET2 [65,73] Mutations in TP53 [74]
Mutations in EZH2 [73,75] Abnormal/complex karyotype [13]
Decreased methylation of the
promoter region of PI-PLCbeta1
[69]
Expression levels of BCL2L10 [14]
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tandardized International Working Group (IWG) 2000 criteria
o assess response [62]. More recently however, some trials and
atient registries are now using the updated IWG  2006 criteria [63].
hanges between the two sets of criteria, including modiﬁed deﬁni-
ions of HI and mCR, need to be taken into account when comparing
tudies.
.2. Are there any biomarkers available to monitor response, or
redict relapse, to azacitidine?
.2.1. Background
Further research is required to identify potential markers that
an effectively predict response and loss of response to azaciti-
ine. Current promising baseline markers include; mutations of
ZH2 [64], TET2 [65], DNMT3A and IDH1/IDH2 [66], BCL2L10 gene
r protein expression levels [14], methylation status of CDKN2B
67], serum ferritin level [68], levels of expression of UCK1 enzyme
15]. Other promising biomarkers for the monitoring of response
o azacitidine during treatment include methylation status of
hosphoinositide-phospholipase C beta 1 [69], increase in platelet
evels after 1–2 cycles of therapy [18,70], and assessment of
eukemic stem cell numbers using ﬂow cytometry as a means of
redicting relapse (Table 3) [71].
.2.2. Views and recommendations of the panel
The panel noted that speciﬁc biomarkers that might predict
esponse/relapse to azacitidine are yet to be validated in a prospec-
ive study, and as a result, none can be recommended at this time.
romising biomarkers should be tested prospectively in large clin-
cal trials.
.3. Are there any factors that may  contribute to relapse that
ight be prevented?
.3.1. Background
Several preventable factors have been postulated to increase
he likelihood of relapse in patients treated with azacitidine. These
nclude early treatment withdrawal and potentially the concomi-
ant use of agents such as hydroxyurea.
Although treatment with azacitidine should be discontinued
f there is evidence of relapse, it is possible that long-term clin-
cal outcomes may  be compromised in patients who  discontinue
zacitidine prematurely. For example, in a recent case series of 13
atients with MDS  who discontinued treatment with azacitidinerch 38 (2014) 1381–1391
while in hematologic remission, 77% relapsed within 6 months
[76]. Moreover, recent multivariate analysis of the AZA-001 trial
has demonstrated that patients who  achieve HI with azacitidine,
but do not achieve CR or PR, are also afforded a survival advan-
tage compared with patients with progressive disease [77]. Notably
however, prolongation of OS in patients who  achieved SD was seen
in both treatment arms [77].
These observations emphasize the importance of routinely
treating patients until overt disease progression, and AEs should be
managed aggressively whenever possible. Furthermore, it is note-
worthy that there are no data indicating transformation potential of
prolonged exposure to azacitidine, nor reports of secondary tumors
in the post-marketing evaluation.
Preclinical studies have demonstrated that hydroxyurea blocks
the conversion of azacitidine to deoxycytidine to inhibit DNA
methylation [78]. This relates to the fact that hydroxyurea is a
ribonucleotide reductase inhibitor that is necessary for azacitidine
to inﬂuence genomic methylation. As a result, in addition to its
antiproliferative effects, hydroxyurea could be antagonistic to azac-
itidine. However, as the activity of azacitidine is also attributable
to its incorporation into RNA as well as DNA [53], its activity may
only be partially inhibited by interaction with hydroxyurea. Nev-
ertheless, in the absence of any clear clinical demonstration of
compatibility, hydroxyurea and azacitidine should be used sequen-
tially rather than concomitantly.
It should also be noted that, to-date, survival beneﬁts with azac-
itidine have only been demonstrated with the approved dose and
schedule of 75 mg/m2 subcutaneous injection for 7 continuous days
every 28 days. Therefore, if possible, this schedule should consti-
tute the preferred treatment for patients with MDS. However, due
to impracticalities of this schedule (i.e. weekends are problematic
in most healthcare systems), there is an ongoing need for collecting
efﬁcacy data from alternative treatment schedules (e.g. 100 mg/m2
for 5 continuous days, 75 mg/m2 on a 5–2–2 schedule, 75 mg/m2
on 5 consecutive days, or intravenous vs. subcutaneous adminis-
tration).
3.3.2. Views and recommendations of the panel
There was  consensus among the panel that in order to minimize
risk of relapse, azacitidine should not be discontinued, if at all possi-
ble, until overt disease progression. Some panel members reported
that in their experience, treatment discontinuation in responding
patients could lead to rapid loss of response and disease progres-
sion. Moreover, they highlighted that patients who prematurely
discontinue azacitidine treatment are unlikely to respond if treat-
ment is resumed.
The panel agreed that the most common reason for discontin-
uation of azacitidine during the ﬁrst few cycles of treatment is
myelosuppression, particularly neutropenia. Although most panel
members routinely manage neutropenia with myeloid growth fac-
tors, they did not think that this was always the case with referring
hematologists. Although some panel members restrict the use of
growth factor to patients with febrile neutropenia, the consensus
was that growth factors should be used in all cases of prolonged
severe neutropenia (ANC < 500 cells/L). This is despite early data
that suggest an increased risk of clonal evolution in patients with
monosomy 7 treated with myeloid growth factors [79]. In addi-
tion, the panel suggested growth factors could be used in patients
at greatest risk for infection, for example those with diabetes, old
age or chronic pulmonary disease. Furthermore, it is important that
growth factor administration is sequenced separately from azaci-
tidine to avoid enhanced uptake of the drug as a result of S phase
recruitment. Given the lack of any formal demonstration of efﬁ-
cacy, there was no consensus amongst the panel regarding the use
of prophylactic antibiotics and antifungals in severely neutropenic
patients. Some panel members routinely use antibiotic prophylaxis
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n patients with MDS  as well as AML. However, emerging data indi-
ate that patients with unfavorable cytogenetics and low platelet
ounts are at high risk of infection and prophylaxis may  only be
articularly appropriate in such cases [80].
The panel also discussed patient-related factors that may  result
n premature discontinuation of treatment. Understandably, a
requent cause of cycle delays and treatment discontinuation is
he inconvenience of repeated injections over 7 days every month
n an outpatient setting. To address this, development of at-home
ursing strategies, combined with a possible oral formulation of
zacitidine will be of particular use for the long-term management
f patients with MDS. It is also important that physicians make
heir patients fully aware of the likely consequences of treatment
ermination.
Finally, the panel debated the role of treatment delays in
he management of AEs. They highlighted that there remains
 lack of consensus among practicing hematologists regarding
hether treatment delay or dose reduction is the best initial
pproach to manage AEs. In general, physicians seem to rely
n personal experience and preference [20,21]. Members of the
anel were uncomfortable with reducing dose, owing to a fear
f losing response (although this is not based on prospective
linical data); therefore, as a ﬁrst option, they prefer extend-
ng the interval between cycles, but only to a maximum of 6
eeks.
. Conclusions
There is a clear unmet clinical need for effective treatments
or patients who have failed azacitidine therapy. Although allo-
eneic HSCT seems to be associated with encouraging outcomes,
ew post-azacitidine patients are eligible. Treatment with azac-
tidine may  facilitate allogeneic HSCT in patients who were
reviously ineligible. While intensive chemotherapy may  beneﬁt
 small minority of patients (e.g. patients undergoing subsequent
SCT), more data are required to assess its role in a salvage
etting. There is considerable ongoing research with investiga-
ional agents following azacitidine failure, but, at present, there
re no ﬁnal and convincing data to guide treatment decisions.
herefore, the panel strongly recommended that patients who
ave failed azacitidine therapy (and are not eligible for HSCT
nd/or intensive chemotherapy) should be enrolled in a clinical
rial.
According to the panel recommendations, when azacitidine
s prescribed, responding patients should be closely monitored
hrough evaluation of PB counts. The most important indicators
f imminent loss of response to azacitidine and/or progression
o AML  are a clear trend toward deteriorating cytopenias and/or
eappearance of RBC-TD in patients who were previously RBC-TI.
f note, deteriorating cytopenias may  take successive measure-
ents over several cycles to conﬁrm due to ﬂuctuations in PB
ounts commonly observed during treatment with azacitidine.
inally, early discontinuation of azacitidine (e.g. due to myelo-
uppression, other AEs or patient request) should be avoided if at
ll possible due to the increased probability of relapse. Treatment
elays and supportive therapies (e.g. myeloid growth factors) are
ecommended in order to manage AEs, and avoid dose reductions
r treatment discontinuation.
In summary, until effective post-azacitidine treatment options
re identiﬁed and supported by prospective clinical data, current
ecommendations should be considered when treating with azaci-
idine. This should ensure maximum clinical beneﬁt is obtained for
atients, who face a poor prognosis should they fail to respond or
ose response to azacitidine.
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